Stay updated with breaking news from Tnf Alpha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a large, retrospective cohort study, investigators found a slightly increased risk for MS in patients on TNF therapy, especially among those being treated for rheumatic disease.
Compared with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologic and targeted synthetic DMARDs may lower dementia risk.
The highest prevalence of HS is among people in their 20s and 30s, so clinicians are likely to encounter female patients with HS who are either pregnant or actively thinking about getting pregnant.
Similar benefits were seen with low, moderate, and high statin doses, as well as in cases of both mild and severe acute pancreatitis.
Subquantifiable brodalumab levels were associated with a lack of response after 12 weeks, in the retrospective study.